153 related articles for article (PubMed ID: 23872799)
1. Prevention of postoperative osteopenia using IV pamidronate: a pilot study.
Hobby BD; Dominguez-Bartmess S; Szalay EA
J Pediatr Orthop; 2013; 33(7):763-7. PubMed ID: 23872799
[TBL] [Abstract][Full Text] [Related]
2. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
4. Quantifying postoperative bone loss in children.
Szalay EA; Harriman D; Eastlund B; Mercer D
J Pediatr Orthop; 2008; 28(3):320-3. PubMed ID: 18362797
[TBL] [Abstract][Full Text] [Related]
5. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
[TBL] [Abstract][Full Text] [Related]
7. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
8. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
10. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
15. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
16. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Henderson RC; Lark RK; Kecskemethy HH; Miller F; Harcke HT; Bachrach SJ
J Pediatr; 2002 Nov; 141(5):644-51. PubMed ID: 12410192
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
[TBL] [Abstract][Full Text] [Related]
19. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
[TBL] [Abstract][Full Text] [Related]
20. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]